China Drug-Capsule Scandal To Increase M&As, Prices, Group Leaders Say
This article was originally published in PharmAsia News
Executive Summary
China’s scandal involving drug capsules made with a potentially toxic industrial gelatin is expected to lead to an increase in mergers and acquisitions in the nation’s drug industry.